Franklin Street Advisors Inc. NC Has $41.94 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Franklin Street Advisors Inc. NC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 83,653 shares of the medical research company’s stock after selling 9,688 shares during the period. Thermo Fisher Scientific makes up about 2.3% of Franklin Street Advisors Inc. NC’s holdings, making the stock its 11th largest holding. Franklin Street Advisors Inc. NC’s holdings in Thermo Fisher Scientific were worth $41,940,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TMO. High Note Wealth LLC raised its position in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $28,000. Legacy Wealth Managment LLC ID grew its stake in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the last quarter. Birchwood Financial Partners Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter worth $29,000. Finally, Core Wealth Advisors LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $30,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.1%

TMO stock opened at $593.11 on Monday. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market cap of $219.30 billion, a PE ratio of 31.90, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. The business’s 50-day simple moving average is $517.63 and its 200 day simple moving average is $509.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. The trade was a 28.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $574.45, for a total transaction of $2,872,250.00. Following the completion of the transaction, the chief executive officer directly owned 9,608 shares of the company’s stock, valued at $5,519,315.60. This trade represents a 34.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,250 shares of company stock worth $12,235,950 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TMO shares. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Piper Sandler boosted their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price on the stock. Royal Bank Of Canada lifted their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Finally, Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.